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Background
Kaposi sarcoma (KS) is one of the most common pedia-
tric cancers in sub-Saharan Africa. Few data are available
about the clinical presentation or response to treatment
of children with epidemic (HIV-associated) KS.
Methods
Medical records of all children with KS and HIV infec-
tion referred to the Uganda Cancer Institute from Octo-
ber 2004 to June 2007 were reviewed. Charts were
abstracted for age, sex, location of KS lesions, biopsy
results, CD4 T-cell counts, and KS treatment and out-
come. (Table 1)
Those children with lymphadenopathic KS were
younger (mean difference 3.7 years; p = 0.01), and had
higher CD4 T-cell counts (mean difference 242 cells/μL;
p = 0.03) than those without lymph node involvement.
CD4 T-cell count was not associated with KS presenta-
tions other than lymph node involvement (Figure 1).
Twenty children (62.5%) of the 32 patients with out-
come data available had a complete resolution of KS.
Eleven patients had a partial response, and only one
patient had a documented lack of response. No associa-
tion was apparent between outcome and age, sex, or type
of KS presentation. Thirty (93.8%) of the 32 patients with
outcome data available received cancer chemotherapy
(10 with vincristine, 20 with vincristine plus bleomycin).
No difference was observed in outcome with respect to
whether cancer chemotherapy was used, or whether one
or two drugs were given. Of those patients with a known
outcome, a higher proportion had a complete resolution
of KS among those who received any antiretroviral ther-
apy (ART) regimen compared to those who did not
receive ART (19 of 26 vs. 1 of 6; P=0.02).
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Table 1
Total Males Females
KS cases, n (percent) 73 (100%) 37 (50.7%) 36 (49.3%)
Age in years, median (range), n=56 10.1 (2 – 18) 9.3 (2 – 16) 11.0 (2 – 18)
CD4 T-cells/uL, median (IQR) n=36 210 (21 – 482) 165 (16 – 538) 263 (26 – 464)
Location of lesions n=42
*
Skin involvement 20 (47.6%) 10 (45.5%) 10 (50.0%)
Oral cavity involvement 9 (21.4%) 4 (20.0%) 5 (22.7%)
Viscera involvement 5 (11.9%) 3 (15.0%) 2 (9.1%)
Lymph node involvement 25 (59.5%) 11 (55.0%) 14 (58.3%)
*Categories of lesion location not mutually exclusive.
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Compared to skin involvement, lymph node involve-
ment of epidemic KS occurs at younger ages and at
higher CD4 levels. This presentation may reflect recent
infection with human herpesvirus 8 followed by a rapid
progression to malignancy. Favorable response to treat-
ment was observed in some cases, but the observed
response rate was almost certainly biased by the large
number of children lost to followup, among whom we
expect disproportionately poor outcomes. Prospective
studies are needed to determine optimal management.
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Figure 1 CD4 T-cell count quartiles (boxes and whiskers) and outliers (dots) for those patients with and without KS involvement of the lymph
nodes (A), skin (B), oral cavity (C), and viscera (D).
Gantt et al. Infectious Agents and Cancer 2010, 5(Suppl 1):A12
http://www.infectagentscancer.com/content/5/S1/A12
Page 2 of 2